Pelthos Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (Unaudited) | ||
| Cash and cash equivalents | $24,192 | $17,973 |
| Restricted cash | 368 | 50 |
| Accounts receivable, net | 14,482 | 8,858 |
| Inventory | 21,472 | 23,574 |
| Prepaid expenses and other current assets | 2,842 | 2,955 |
| Total current assets | 63,356 | 53,410 |
| Property and equipment, net | 8,881 | 9,586 |
| Operating lease right-of-use assets, net | 3,041 | 3,250 |
| Intangible assets, net | 37,397 | 39,470 |
| Goodwill | 24,681 | 24,681 |
| Total assets | $137,356 | $130,397 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Accounts payable | $5,853 | $2,986 |
| Accrued expenses | 20,745 | 15,364 |
| Contingent consideration | 1,000 | 2,200 |
| Operating lease liabilities, current portion | 645 | 635 |
| Deferred revenue, current portion | 729 | 966 |
| Other liabilities | 1,527 | 1,963 |
| Other liabilities - related party | 1,460 | 1,879 |
| Total current liabilities | 31,959 | 25,993 |
| Operating lease liabilities, net of current portion | 2,550 | 2,752 |
| Deferred revenue, net of current portion | 1,093 | 1,280 |
| Convertible notes payable - related party | 43,321 | 31,441 |
| Venture loan and security agreement, net | 26,593 | — |
| Other long-term liabilities | 20,406 | 18,908 |
| Other long-term liabilities - related party | 12,935 | 11,142 |
| Total liabilities | 138,857 | 91,516 |
| Commitments and contingencies (Note 11) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock Series A, $0.0001 par value, 150,000 shares authorized, 52,128 and 56,418 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 3,718,624 and 3,234,423 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid in capital | 109,705 | 103,675 |
| Accumulated other comprehensive income | 2,078 | — |
| Accumulated deficit | (113,284) | (64,794) |
| Total stockholders' (deficit) equity | (1,501) | 38,881 |
| Total liabilities and stockholders' equity | $137,356 | $130,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.